Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Ivan Pećin & Željko Reiner. (2021) Novel Experimental Agents for the Treatment of Hypercholesterolemia. Journal of Experimental Pharmacology 13, pages 91-100.
Read now
Read now
Rana Shafabakhsh, Željko Reiner, Jamal Hallajzadeh, Liaosadat Mirsafaei & Zatollah Asemi. (2021) Are anti-inflammatory agents and nutraceuticals - novel inhibitors of PCSK9?. Critical Reviews in Food Science and Nutrition 61:2, pages 325-336.
Read now
Read now
Svetlana Moşteoru, Dan Gaiţă & Maciej Banach. (2020) An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity. Expert Opinion on Drug Metabolism & Toxicology 16:12, pages 1199-1205.
Read now
Read now
Etienne Khoury, Diane Brisson & Daniel Gaudet. (2020) Preclinical discovery and development of evolocumab for the treatment of hypercholesterolemia. Expert Opinion on Drug Discovery 15:4, pages 403-414.
Read now
Read now
Andrea Pasta, Anna Laura Cremonini, Livia Pisciotta, Angelo Buscaglia, Italo Porto, Fabio Barra, Simone Ferrero, Claudio Brunelli & Gian Marco Rosa. (2020) PCSK9 inhibitors for treating hypercholesterolemia. Expert Opinion on Pharmacotherapy 21:3, pages 353-363.
Read now
Read now
Marilisa Bove, Arrigo F.G. Cicero & Claudio Borghi. (2019) Emerging drugs for the treatment of hypercholesterolemia. Expert Opinion on Emerging Drugs 24:1, pages 63-69.
Read now
Read now
Constantine E Kosmas, Delia Silverio, Julio Ovalle, Peter D Montan & Eliscer Guzman. (2018) Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia. Patient Preference and Adherence 12, pages 2263-2266.
Read now
Read now
Gerald Fitzgerald & Tom Kiernan. (2018) PCSK9 inhibitors and LDL reduction: pharmacology, clinical implications, and future perspectives. Expert Review of Cardiovascular Therapy 16:8, pages 567-578.
Read now
Read now
Vybhav Jetty, Charles J Glueck, Kevin Lee, Naila Goldenberg, Marloe Prince, Ashwin Kumar, Michael Goldenberg, Ishan Anand & Ping Wang. (2017) Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy. Vascular Health and Risk Management 13, pages 247-253.
Read now
Read now
Maria Drakopoulou, Konstantinos Toutouzas, Konstantinos Stathogiannis, Andreas Synetos, George Trantalis & Dimitrios Tousoulis. (2016) Managing the lipid profile of coronary heart disease patients. Expert Review of Cardiovascular Therapy 14:11, pages 1263-1271.
Read now
Read now
Alain Beck, Guillaume Terral, François Debaene, Elsa Wagner-Rousset, Julien Marcoux, Marie-Claire Janin-Bussat, Olivier Colas, Alain Van Dorsselaer & Sarah Cianférani. (2016) Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates. Expert Review of Proteomics 13:2, pages 157-183.
Read now
Read now
Articles from other publishers (23)
Gabriela Alexandra Solano Peña, Gabriela Fernanda Acurio Armas, Gabriela Alejandra Díaz Teran, Susana Patricia Palacios Serrano, Andrea Carolina Cobo Reyes, Daniel Albino Pullas Taboada & Gissel Katherine Carvajal Chango. (2023) Inhibición de PCSK9: una nueva alternativa para reducir el colesterol y prevenir la enfermedad cardiovascular aterosclerosa. Salud, Ciencia y Tecnología 3, pages 587.
Crossref
Crossref
Forough Taheri, Eskandar Taghizadeh, Fatemeh Baniamerian, Daryoush Rostami, Ahmad Rozeian, Seyed Mohammad Gheibi hayat, Tannaz Jamialahmadi, Željko Reiner & Amirhossein Sahebkar. (2022) Cellular and Molecular Aspects of Managing Familial Hypercholesterolemia: Recent and Emerging Therapeutic Approaches. Endocrine, Metabolic & Immune Disorders - Drug Targets 22:10, pages 1018-1028.
Crossref
Crossref
Chayakrit Krittanawong, Muzamil Khawaja, Robert S Rosenson, Christopher I. Amos, Vijay Nambi, Carl J Lavie & Salim S. Virani. (2022) Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy. Current Problems in Cardiology 47:7, pages 101043.
Crossref
Crossref
Elke Bouwens, Anne-Sophie Schuurman, K Martijn Akkerhuis, Olivier C Manintveld, Kadir Caliskan, Jan van Ramshorst, Tjeerd Germans, Victor AWM Umans, Eric Boersma & Isabella Kardys. (2021) Associations of serially measured PCSK9, LDLR and MPO with clinical outcomes in heart failure. Biomarkers in Medicine 15:4, pages 247-255.
Crossref
Crossref
Alberto J Lorenzatti & Peter P Toth. (2020) New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease. European Cardiology Review 15.
Crossref
Crossref
Tannaz Jamialahmadi, Yunes Panahi, Mohamamd Amin Safarpour, Shiva Ganjali, Mahdi Chahabi, Zeljko Reiner, Saeed Solgi, Amir Vahedian-azimi, Parisa Kianpour, Maciej Banach & Amirhossein Sahebkar. (2019) Association of Serum PCSK9 Levels with Antibiotic Resistance and Severity of Disease in Patients with Bacterial Infections Admitted to Intensive Care Units. Journal of Clinical Medicine 8:10, pages 1742.
Crossref
Crossref
Željko Reiner. (2019) The association between lipid-lowering drugs and circulating concentration of PCSK9. European Journal of Preventive Cardiology 26:9, pages 928-929.
Crossref
Crossref
Ivana Veljić, Marija Polovina, Ivan Milinković & Petar M Seferović. (2018) Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 inhibitors: Do we have a vanquishing new strategy?. European Journal of Preventive Cardiology 26:7, pages 739-742.
Crossref
Crossref
Manuela Casula, Elena Olmastroni, Mezio T. Boccalari, Elena Tragni, Angela Pirillo & Alberico L. Catapano. (2019) Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials. Pharmacological Research 143, pages 143-150.
Crossref
Crossref
Željko Reiner. (2019) Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?. Current Atherosclerosis Reports 21:4.
Crossref
Crossref
Zonglei Zhao, Song Du, Shuxin Shen, Ping Luo, Shoukun Ding, Guanggong Wang & Lixia Wang. (2019) Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia. Medicine 98:6, pages e14400.
Crossref
Crossref
Federico Bigazzi, Francesco Sbrana, Daniele Berretti, Zenti Maria Grazia, Sabina Zambon, Antonia Fabris, Maurizio Fonda, Giovanni B. Vigna, Giovanna D’Alessandri, Stefano Passalacqua, Beatrice Dal Pino, Mascia Pianelli, Roberta Luciani, Andrea Ripoli, Daniela Rafanelli, Enzo Manzato, Luigi Cattin & Tiziana Sampietro. (2018) Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study. Transfusion and Apheresis Science 57:5, pages 661-664.
Crossref
Crossref
Željko Reiner. (2018) Treatment of children with homozygous familial hypercholesterolaemia. European Journal of Preventive Cardiology 25:10, pages 1095-1097.
Crossref
Crossref
Ankita Solanki, Lokesh Kumar Bhatt & Thomas P. Johnston. (2018) Evolving targets for the treatment of atherosclerosis. Pharmacology & Therapeutics 187, pages 1-12.
Crossref
Crossref
Farzad Khademi, Amir Abbas Momtazi-borojeni, Željko Reiner, Maciej Banach, Khalid Al Al-Rasadi & Amirhossein Sahebkar. (2018) PCSK9 and infection: A potentially useful or dangerous association?. Journal of Cellular Physiology 233:4, pages 2920-2927.
Crossref
Crossref
Željko Reiner. (2018) PCSK9 inhibitors in clinical practice: Expectations and reality. Atherosclerosis 270, pages 187-188.
Crossref
Crossref
Raul Cavalcante Maranhão, Antonio Casela Filho, Gilbert Alexandre Sigal, Antonio Carlos Palandri Chagas & Protásio Lemos da Luz. 2018. Endothelium and Cardiovascular Diseases. Endothelium and Cardiovascular Diseases
297
317
.
Claudia Stefanutti, Fabio Mazza, Dario Mesce, Claudia Morozzi, Serafina Di Giacomo, Marco Vitale & Mario Pergolini. (2017) Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study. Atherosclerosis Supplements 30, pages 86-91.
Crossref
Crossref
Ivan Pećin, Merel L Hartgers, G Kees Hovingh, Ricardo Dent & Željko Reiner. (2017) Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. European Journal of Preventive Cardiology 24:13, pages 1383-1401.
Crossref
Crossref
Paul S. Jellinger, Yehuda Handelsman, Paul D. Rosenblit, Zachary T. Bloomgarden, Vivian A. Fonseca, Alan J. Garber, George Grunberger, Chris K. Guerin, David S.H. Bell, Jeffrey I. Mechanick, Rachel Pessah-Pollack, Kathleen Wyne, Donald Smith, Eliot A. Brinton, Sergio Fazio, Michael Davidson, Paul S. Jellinger, Yehuda Handelsman, David S.H. Bell, Zachary T. Bloomgarden, Eliot A. Brinton, Michael H. Davidson, Sergio Fazio, Vivian A. Fonseca, Alan J. Garber, George Grunberger, Chris K. Guerin, Jeffrey I. Mechanick, Rachel Pessah-Pollack, Paul D. Rosenblit, Donald A. Smith, Kathleen Wyne, Michael Bush, Farhad Zangeneh, Yehuda Handelsman, David S.H. Bell, Zachary T. Bloomgarden, Eliot A. Brinton, Sergio Fazio, Vivian A. Fonseca, Alan J. Garber, George Grunberger, Chris K. Guerin, Paul S. Jellinger, Paul D. Rosenblit, Donald A. Smith, Kathleen Wyne & Michael H. Davidson. (2017) American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice 23, pages 1-87.
Crossref
Crossref
K. Yadav, M. Sharma & K.C. Ferdinand. (2016) Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Nutrition, Metabolism and Cardiovascular Diseases 26:10, pages 853-862.
Crossref
Crossref
Chanukya Dahagam, Aditya Goud, Abdelhai Abdelqader, Aditya Hendrani, Matthew J Feinstein, Arman Qamar, Parag H Joshi, Kristopher J Swiger, Kathleen Byrne, Renato Quispe, Steven R Jones, Roger S Blumenthal & Seth S Martin. (2016) PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab. Future Cardiology 12:2, pages 149-157.
Crossref
Crossref
?. Reiner, G. De Backer, Z. Fras, K. Kotseva, L. Tokg?zoglu, D. Wood & D. De Bacquer. (2016) Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries ? Findings from the EUROASPIRE IV survey. Atherosclerosis 246, pages 243-250.
Crossref
Crossref